BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Sirica AE, Strazzabosco M, Cadamuro M. Intrahepatic cholangiocarcinoma: Morpho-molecular pathology, tumor reactive microenvironment, and malignant progression. Adv Cancer Res 2021;149:321-87. [PMID: 33579427 DOI: 10.1016/bs.acr.2020.10.005] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Wu Y, Hayat K, Hu Y, Yang J. Long Non-Coding RNAs as Molecular Biomarkers in Cholangiocarcinoma. Front Cell Dev Biol 2022;10:890605. [DOI: 10.3389/fcell.2022.890605] [Reference Citation Analysis]
2 Marin JJ, Macias RI. Understanding drug resistance mechanisms in cholangiocarcinoma: assisting the clinical development of investigational drugs. Expert Opin Investig Drugs 2021;30:675-9. [PMID: 33934687 DOI: 10.1080/13543784.2021.1916912] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
3 Guan C, Liu L, Zhao Y, Zhang X, Liu G, Wang H, Gao X, Zhong X, Jiang X. YY1 and eIF4A3 are mediators of the cell proliferation, migration and invasion in cholangiocarcinoma promoted by circ-ZNF609 by targeting miR-432-5p to regulate LRRC1. Aging (Albany NY) 2021;13:25195-212. [PMID: 34898474 DOI: 10.18632/aging.203735] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Brindley PJ, Bachini M, Ilyas SI, Khan SA, Loukas A, Sirica AE, Teh BT, Wongkham S, Gores GJ. Cholangiocarcinoma. Nat Rev Dis Primers 2021;7:65. [PMID: 34504109 DOI: 10.1038/s41572-021-00300-2] [Reference Citation Analysis]